Sanofi Partners with Alloy Therapeutics in $400M Deal to Advance Antisense Therapeutics
Partnership Agreement:
Sanofi has entered into a $400M biobucks deal with Alloy Therapeutics to test the potential of Alloy's antisense platform, specifically the AntiClastic Antisense Oligonucleotide (ASO) technology35.
Technology Overview:
Alloy's AntiClastic ASO platform is designed to overcome traditional limitations in antisense therapeutics by improving potency, delivery to target RNA, and minimizing off-target interactions and inflammatory responses15.
Collaboration Model:
Alloy Therapeutics offers a collaborative model where partners can provide gene targets or existing antisense sequences to be converted into AntiClastic ASO formats, with shared risk and success through flexible research and partnership terms15.
Strategic Focus:
This partnership aligns with Sanofi's "Play to Win" strategy, which emphasizes investing in transformative medicine and vaccines, enhancing R&D productivity, and driving long-term growth4.
Future Prospects:
The deal reflects Sanofi's commitment to advancing genetic medicine and leveraging innovative technologies to address complex diseases, with potential applications in various therapeutic areas including the central nervous system, liver, muscles, and ocular diseases14.
Sources:
1. https://alloytx.com/2023/06/28/anticlastic-antisense-oligonucleotide/
3. https://www.fiercebiotech.com/biotech/lb-pharmas-twist-old-sanofi-drug-passes-schizophrenia-test-teeing-phase-3-push
4. https://www.sanofi.com/en/media-room/press-releases/2023/2023-10-27-05-30-00-2768148